PE20230854A1 - Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos - Google Patents
Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismosInfo
- Publication number
- PE20230854A1 PE20230854A1 PE2023000103A PE2023000103A PE20230854A1 PE 20230854 A1 PE20230854 A1 PE 20230854A1 PE 2023000103 A PE2023000103 A PE 2023000103A PE 2023000103 A PE2023000103 A PE 2023000103A PE 20230854 A1 PE20230854 A1 PE 20230854A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heteroaryl
- dihydroimidazolone
- tetrahydropyrazole
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referida a un compuesto de formula (I), donde X es C o N; Y es NR1 o CR1; R1 es (CRCRC)0-2-cicloalquilo de C3 a C6, (CRCRC)0-2-fenilo, o (CRCRC)0-2-heteroarilo que comprende un anillo de 5 o 6 miembros y de 1 a 3 heteroatomos que se seleccionan a partir de N, O y S, en donde el cicloalquilo, fenilo o heteroarilo se sustituye opcionalmente con alquilo de C1 a C6, haloalquilo de C1 a C6, entre otros; cada RC es H, alquilo de C1 a C3 o haloalquilo de C1 a C3; R2 es cicloalquilo de C3 a C10, fenilo, heterociclilo que comprende uno o dos anillos de 5 o 6 miembros y de 1 a 3 heteroatomos que se seleccionan a partir de N, O y S, o heteroarilo que comprende uno o dos anillos de 5 o 6 miembros y de 1 a 3 heteroatomos que se seleccionan a partir de N, O y S, en donde el cicloalquilo, fenilo, heterociclilo o heteroarilo se sustituye opcionalmente con alquilo de C1 a C6, entre otros; A es un anillo heteroarilo biciclo; R4 es alquilo de C1 a C6, haloalquilo de C1 a C6, alcoxilo de C1 a C6, haloalcoxilo de C1 a C6, NH- (alquilo de C1 a C6), N (alquilo de C1 a C6)2 o CN; L es -CR5R6- o fenileno; R5 y R6 son H, alquilo de C1 a C6, haloalquilo de C1 a C6, alcoxilo de C1 a C6, haloalcoxilo de C1 a C6, OH, entre otros; T es C(O)OH, (CH2)NHS(O)2- (alquilo de C1 a C6), o heteroarilo que comprende un anillo de 5 o 6 miembros y de 1 a 3 heteroatomos que se seleccionan a partir de N, O y S, en donde el heteroarilo se sustituye de opcionalmente con alquilo de C1 a C6, haloalquilo de C1 a C6, entre otros. Dichos compuestos modulan la actividad del receptor de GLP-1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020102955 | 2020-07-20 | ||
| CN2021070120 | 2021-01-04 | ||
| PCT/CN2021/107216 WO2022017338A1 (en) | 2020-07-20 | 2021-07-20 | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230854A1 true PE20230854A1 (es) | 2023-05-29 |
Family
ID=77167918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000103A PE20230854A1 (es) | 2020-07-20 | 2021-07-20 | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12037339B2 (es) |
| EP (1) | EP4182020A1 (es) |
| JP (1) | JP2023534983A (es) |
| KR (1) | KR20230048056A (es) |
| CN (1) | CN116390926A (es) |
| AU (1) | AU2021311567A1 (es) |
| BR (1) | BR112023000932A2 (es) |
| CA (1) | CA3186217A1 (es) |
| CL (1) | CL2023000196A1 (es) |
| CO (1) | CO2023001407A2 (es) |
| IL (1) | IL299704A (es) |
| MX (1) | MX2023000943A (es) |
| PE (1) | PE20230854A1 (es) |
| WO (1) | WO2022017338A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024125624A1 (en) * | 2022-12-15 | 2024-06-20 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| WO2024153070A1 (en) * | 2023-01-17 | 2024-07-25 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN111801331A (zh) | 2018-02-28 | 2020-10-20 | 诺华股份有限公司 | 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途 |
-
2021
- 2021-07-20 BR BR112023000932A patent/BR112023000932A2/pt unknown
- 2021-07-20 CA CA3186217A patent/CA3186217A1/en active Pending
- 2021-07-20 JP JP2023504008A patent/JP2023534983A/ja active Pending
- 2021-07-20 EP EP21749074.7A patent/EP4182020A1/en active Pending
- 2021-07-20 WO PCT/CN2021/107216 patent/WO2022017338A1/en active Application Filing
- 2021-07-20 IL IL299704A patent/IL299704A/en unknown
- 2021-07-20 CN CN202180063652.8A patent/CN116390926A/zh active Pending
- 2021-07-20 AU AU2021311567A patent/AU2021311567A1/en active Pending
- 2021-07-20 MX MX2023000943A patent/MX2023000943A/es unknown
- 2021-07-20 PE PE2023000103A patent/PE20230854A1/es unknown
- 2021-07-20 US US17/380,084 patent/US12037339B2/en active Active
- 2021-07-20 KR KR1020237005845A patent/KR20230048056A/ko active Search and Examination
- 2021-11-02 US US17/516,932 patent/US11584751B1/en active Active
-
2023
- 2023-01-19 CL CL2023000196A patent/CL2023000196A1/es unknown
- 2023-02-09 CO CONC2023/0001407A patent/CO2023001407A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116390926A (zh) | 2023-07-04 |
| MX2023000943A (es) | 2023-02-22 |
| IL299704A (en) | 2023-03-01 |
| BR112023000932A2 (pt) | 2023-10-03 |
| AU2021311567A1 (en) | 2023-02-16 |
| CL2023000196A1 (es) | 2023-09-15 |
| US12037339B2 (en) | 2024-07-16 |
| CA3186217A1 (en) | 2022-01-27 |
| CO2023001407A2 (es) | 2023-02-16 |
| EP4182020A1 (en) | 2023-05-24 |
| US11584751B1 (en) | 2023-02-21 |
| KR20230048056A (ko) | 2023-04-10 |
| WO2022017338A1 (en) | 2022-01-27 |
| JP2023534983A (ja) | 2023-08-15 |
| US20230051320A1 (en) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230854A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos | |
| PE20221283A1 (es) | Compuestos triciclicos sustituidos | |
| PE20231206A1 (es) | Compuestos como agonistas de glp-1r | |
| AR113688A1 (es) | Proceso para la preparación de compuestos de piridiminio ópticamente activo | |
| AR117200A1 (es) | Derivados de tiazol microbiocidas | |
| CO4940442A1 (es) | Derivados de 4-bromo o 4-yodo fenilamino acido benzhidroxamico | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR018917A1 (es) | Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. | |
| PE20090068A1 (es) | Compuestos de anillo fusionado como agonistas parciales de ppar gamma | |
| SV1999000119A (es) | Benzazoles consistentes en derivados de benzoxazol, benzthiazol y benzimidazol | |
| AR055016A1 (es) | Aminoalcoholes triciclicos, procedimientos para su preparacion y su uso para la preparacion de medicamentos | |
| PE20001643A1 (es) | Uso de antagonistas de crf que mejora la dispersion de qt y la variabilidad de la frecuencia cardiaca para prevenir muerte subita | |
| AR089871A1 (es) | Derivados de arilalquiloxipirimidina e insecticidas agrohorticolas que comprenden dichos derivados como principios activos, y metodo de uso de los mismos | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| CO5700817A2 (es) | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo | |
| CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
| AR063335A1 (es) | Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico | |
| AR043837A1 (es) | Pirazoles sustituidos | |
| CO6190609A2 (es) | Compuestos de urea policiclicos antibacterianos | |
| PE20221402A1 (es) | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| PE20150598A1 (es) | Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1 | |
| AR066603A1 (es) | Derivados de arilamida pirimidona |